Stanford Team Performs First Islet Transplant with Experimental Immune Tolerance Protocol

In May 2025, a multidisciplinary team at Stanford Medicine gathered to perform a procedure that marked years of collaborative research and development. The case involved an islet cell transplant—a procedure in which insulin-producing cells harvested from a donor pancreas are infused into a patient's liver. What made this case distinctive was not the transplant itself, but the accompanying experimental immune tolerance protocol designed to help the recipient's body accept the donor cells more readily.

Islet cell transplantation is not new, but the challenge has always been keeping transplanted cells alive long-term. Typically, transplant recipients require lifelong immunosuppressive medications to prevent their immune system from attacking the donor cells. These medications carry significant side effects and require careful management.

Stanford's SPIRIT (pancreatic Islet Transplantation and immune tolerance initiative) program is exploring whether an experimental immune tolerance protocol can change this equation. By helping the body better accept donor cells, the protocol aims to reduce or potentially eliminate the need for long-term immunosuppression—a significant goal for transplant medicine.

Islet cell transplantation is typically considered for patients with Type 1 diabetes who face the most serious complications of the disease. One critical group includes people who have developed hypoglycemia unawareness—the loss of the ability to sense when their blood sugar is dropping dangerously low. This condition makes blood sugar management extremely difficult and puts patients at high risk for severe, life-threatening episodes.

For these patients, a successful islet transplant that reduces dependence on immunosuppressive drugs could be genuinely life-changing, offering greater metabolic stability and improved quality of life.

This first case under Stanford's SPIRIT protocol is an important step in islet transplantation research, but it represents a beginning rather than a conclusion. The procedure demonstrates the feasibility of combining islet transplantation with immune tolerance strategies, and the team will continue studying outcomes to understand the full potential of this approach.

For the broader Type 1 diabetes community, this work underscores the ongoing effort to develop treatments that address not just blood sugar management, but the underlying immune dysfunction that drives the disease. As research continues, insights from this case may help shape future approaches to transplantation and immune tolerance.

Origin: Department of Medicine (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.